JP6883590B2 - Ｐｄ−ｌ１に結合する抗原結合性タンパク質 - Google Patents

Ｐｄ−ｌ１に結合する抗原結合性タンパク質 Download PDF

Info

Publication number
JP6883590B2
JP6883590B2 JP2018559164A JP2018559164A JP6883590B2 JP 6883590 B2 JP6883590 B2 JP 6883590B2 JP 2018559164 A JP2018559164 A JP 2018559164A JP 2018559164 A JP2018559164 A JP 2018559164A JP 6883590 B2 JP6883590 B2 JP 6883590B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
variable domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018559164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507183A (ja
JP2019507183A5 (https=
Inventor
ジョウ・ヘユー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of JP2019507183A publication Critical patent/JP2019507183A/ja
Publication of JP2019507183A5 publication Critical patent/JP2019507183A5/ja
Priority to JP2021047470A priority Critical patent/JP7140867B2/ja
Application granted granted Critical
Publication of JP6883590B2 publication Critical patent/JP6883590B2/ja
Priority to JP2022067548A priority patent/JP2022095910A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
JP2018559164A 2016-01-29 2017-01-27 Ｐｄ−ｌ１に結合する抗原結合性タンパク質 Active JP6883590B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021047470A JP7140867B2 (ja) 2016-01-29 2021-03-22 Ｐｄ－ｌ１に結合する抗原結合性タンパク質
JP2022067548A JP2022095910A (ja) 2016-01-29 2022-04-15 Ｐｄ－ｌ１に結合する抗原結合性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29
US62/288,912 2016-01-29
PCT/US2017/015429 WO2017132562A1 (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021047470A Division JP7140867B2 (ja) 2016-01-29 2021-03-22 Ｐｄ－ｌ１に結合する抗原結合性タンパク質

Publications (3)

Publication Number Publication Date
JP2019507183A JP2019507183A (ja) 2019-03-14
JP2019507183A5 JP2019507183A5 (https=) 2019-12-26
JP6883590B2 true JP6883590B2 (ja) 2021-06-09

Family

ID=59386438

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559164A Active JP6883590B2 (ja) 2016-01-29 2017-01-27 Ｐｄ−ｌ１に結合する抗原結合性タンパク質
JP2021047470A Active JP7140867B2 (ja) 2016-01-29 2021-03-22 Ｐｄ－ｌ１に結合する抗原結合性タンパク質
JP2022067548A Pending JP2022095910A (ja) 2016-01-29 2022-04-15 Ｐｄ－ｌ１に結合する抗原結合性タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021047470A Active JP7140867B2 (ja) 2016-01-29 2021-03-22 Ｐｄ－ｌ１に結合する抗原結合性タンパク質
JP2022067548A Pending JP2022095910A (ja) 2016-01-29 2022-04-15 Ｐｄ－ｌ１に結合する抗原結合性タンパク質

Country Status (17)

Country Link
US (4) US10118963B2 (https=)
EP (1) EP3408400B1 (https=)
JP (3) JP6883590B2 (https=)
KR (2) KR20260041830A (https=)
CN (2) CN116333124A (https=)
AU (1) AU2017212717B2 (https=)
BR (1) BR112018015480A2 (https=)
CA (1) CA3013051A1 (https=)
CL (1) CL2018002034A1 (https=)
EA (1) EA037855B1 (https=)
ES (1) ES2986360T3 (https=)
IL (1) IL260846B2 (https=)
MX (2) MX2018009228A (https=)
PH (1) PH12018501611A1 (https=)
SG (1) SG11201806496SA (https=)
TW (1) TWI760323B (https=)
WO (1) WO2017132562A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1204557A1 (en) * 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EA037855B1 (ru) 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN119899267A (zh) * 2018-03-22 2025-04-29 赛因格先进生物技术弗朗哥塞尔瓦托有限责任公司 拮抗性pd-1、pd-l1和lag-3结合蛋白
AU2018418224B2 (en) 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
KR20210056288A (ko) * 2018-06-01 2021-05-18 타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
US12391758B2 (en) 2018-08-20 2025-08-19 1Globe Biomedical Co., Ltd. Anti-PD-L1 cancer immunotherapy antibodies
EP3893902B1 (en) * 2018-12-11 2024-10-23 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of pd-l1 activity or expression for use in the treatment of serrated colorectal cancer
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
WO2020215020A1 (en) * 2019-04-18 2020-10-22 Qlsf Biotherapeutics Inc. Humanized anti-pd-l1 antibodies
WO2021037007A1 (zh) * 2019-08-29 2021-03-04 荣昌生物制药(烟台)股份有限公司 抗pd-l1抗体及其应用
MX2023000005A (es) * 2020-06-26 2023-03-06 Sorrento Therapeutics Inc Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras.
EP4208204A1 (en) 2020-09-02 2023-07-12 Mayo Foundation for Medical Education and Research Antibody-nanoparticle complexes and methods for making and using the same
JP2023552694A (ja) 2020-11-16 2023-12-19 イミューンオンシア セラピューティクス インコーポレイテッド 免疫抗がん剤に対する治療反応性を予測するためのバイオマーカーおよびその用途
MX2023012995A (es) 2021-05-07 2023-12-14 Immuneoncia Therapeutics Inc Anticuerpo biespecífico que se enlaza específicamente a cd47 y pd-l1.
US20240279339A1 (en) 2021-06-09 2024-08-22 Vivasor, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
CA3267341A1 (en) * 2022-09-19 2024-03-28 Sonoma Biotherapeutics, Inc. Specific chimeric antigen receptors for a citrullinated antigen to target regulatory T lymphocytes for the treatment of hidradenitis suppurativa
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
TW202544031A (zh) * 2024-02-29 2025-11-16 南韓商柳韓洋行股份有限公司 抗tigit/抗pd-l1雙特異性抗體及其用途
IL323020A (en) * 2024-04-13 2026-03-01 Immuneoncia Therapeutics Inc Neoadjuvant immunotherapy with a PD-L1 inhibitor for cancer treatment
KR20250165706A (ko) 2024-04-13 2025-11-27 주식회사 이뮨온시아 암 치료를 위한 pd-l1 저해제를 이용한 신보조요법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
AU673190B2 (en) 1992-07-13 1996-10-31 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
SI2162149T1 (sl) 2007-06-01 2014-04-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cepivo za preprečevanje relapsa raka na dojki
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9676853B2 (en) * 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
WO2015154052A1 (en) * 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
EA037855B1 (ru) * 2016-01-29 2021-05-27 Сорренто Терапьютикс, Инк. Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1

Also Published As

Publication number Publication date
MX2022011659A (es) 2022-10-13
CN109715821B (zh) 2022-09-06
JP2019507183A (ja) 2019-03-14
US20190092861A1 (en) 2019-03-28
ES2986360T3 (es) 2024-11-11
MX2018009228A (es) 2019-07-08
CN116333124A (zh) 2023-06-27
US20210147539A1 (en) 2021-05-20
JP2021102633A (ja) 2021-07-15
EA201891709A1 (ru) 2019-01-31
TWI760323B (zh) 2022-04-11
BR112018015480A2 (pt) 2019-05-21
PH12018501611A1 (en) 2019-04-08
US10118963B2 (en) 2018-11-06
TW201736400A (zh) 2017-10-16
KR20190026642A (ko) 2019-03-13
WO2017132562A1 (en) 2017-08-03
IL260846B2 (en) 2023-02-01
JP2022095910A (ja) 2022-06-28
US20240190959A1 (en) 2024-06-13
EA037855B1 (ru) 2021-05-27
CN109715821A (zh) 2019-05-03
US11919952B2 (en) 2024-03-05
WO2017132562A8 (en) 2017-09-08
AU2017212717B2 (en) 2023-11-16
KR20260041830A (ko) 2026-03-27
EP3408400C0 (en) 2024-06-26
KR102927822B1 (ko) 2026-02-13
AU2017212717A1 (en) 2018-09-06
EP3408400A1 (en) 2018-12-05
EP3408400A4 (en) 2019-11-27
NZ745357A (en) 2025-08-29
US20170218066A1 (en) 2017-08-03
CL2018002034A1 (es) 2019-03-15
IL260846B (en) 2022-10-01
SG11201806496SA (en) 2018-08-30
JP7140867B2 (ja) 2022-09-21
EP3408400B1 (en) 2024-06-26
IL260846A (https=) 2018-09-20
US10919964B2 (en) 2021-02-16
CA3013051A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
JP6883590B2 (ja) Ｐｄ−ｌ１に結合する抗原結合性タンパク質
JP7624573B2 (ja) Ｐｄ－１に結合する抗原結合蛋白質
JP6829330B2 (ja) Ｐｄ−ｌ１に結合する抗原結合蛋白質
JP2015520172A (ja) Ｄｌｌ−４に結合する抗原結合蛋白質
JP2017529331A (ja) Ｃｘｃｒ３に結合する抗原結合タンパク質

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191115

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20201112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210510

R150 Certificate of patent or registration of utility model

Ref document number: 6883590

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250